Objectives: Recurrent cytogenetic abnormalities and/or molecular aberrations play an important role in the diagnosis and prognostification of acute myeloid leukemia (AML). We describe a case of a 40 year old woman diagnosed with de novo AML with a novel t(7;14)(q21,q32) and trisomy 4 with poor clinical outcome.
Acute myeloid leukemia (AML) is a clonal hematopoietic disorder and, per definition, requires blasts or blast equivalents to account for 20% or more of the peripheral blood and/or bone marrow cellularity, or otherwise display certain recurrent cytogenetic abnormalities in presence of less than 20% blasts. Classification of AML relies on morphology, immunophenotype, cytogenetic abnormalities, and more recently, molecular studies. The World Health Organization (WHO) 2008 classification and the newly modified WHO 2016 classification for myeloid neoplasms has recognized a distinct group of AMLs with specific recurrent cytogenetic
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abnormalities.
1,2 Cytogenetic and also molecular abnormalities are important not only in the classification of acute myeloid leukemia but also for disease prognostication.
Here, we report a case of acute myeloid leukemia with a rare translocation involving 7q21 and 14q32 and trisomy 4 with poor response to induction chemotherapy.
Materials and Methods
The peripheral blood (PB) smears, bone marrow (BM) aspirate smears, touch imprints, and core biopsy specimens were examined at presentation, 14 days post induction, and post re-induction chemotherapy. The PB and BM samples were subjected to immunophenotypic studies by flow cytometry and conventional cytogenetic analysis using standard techniques. 
Results
The patient is a 40-year-old Hispanic woman who presented with significant fatigue and somnolence for two weeks. The diagnostic bone marrow (BM) biopsy was hypercellular for age (>95%) with increased blasts, accounting for 62% of marrow cellularity (Images 1A and B). Flow cytometry revealed an expanded population of immunophenotypically aberrant hematolymphoid blasts (81%) that demonstrate evidence of myeloid differentiation with a few T/NK lineage markers, but it was negative for cytoplasmic CD3 and thus did not show evidence for a mixed phenotype acute leukemia (Image 2A). Conventional karyotype analysis performed on the BM showed 47, XX, +4, t(7;14)(q21;q32) ).
A BM biopsy was performed following re-induction to evaluate response. CBC at this time was as follows: WBCs,
Image 1
A, Wright Geimsa stained marrow aspirate, 100x, with many blasts (white arrow), in a background of morphologically normal megakaryocyte (M), granulocyte precursor(s) (G), mature lymphocyte (black arrow). B, Core biopsy shows a hypercellular bone marrow (4x). There are scattered maturing granulocytes with numerous granulocytes (inset).
Image 2
A, Flow cytometry of the diagnostic bone marrow shows acute myeloid leukemia with a 81% population of variably-sized blasts with the following immunophenotype: CD2 (appears dim +), CD11b(-), CD13(+), CD14(-), CD15(variably +), CD33(-), CD34(+), CD38(bright +), CD45(variably +), CD56(+), CD117(+), and HLA-DR(partial dim+ to -). B, Conventional cytogenetics analysis shows an abnormal karyotype with trisomy of chromosome 4 and a translocation involving the long arms of chromosome 7 and 14. 47, XX, t(7;14)(q21;q32) (translocation, arrows). C, Metaphase-FISH with IgH break apart probe shows der(7) with IgH probe (black arrow) and der(14)t(7;14) (red arrow). /L. The PB smear continued to show pancytopenia. The BM was 10% cellular with increased blasts (45%) with similar immunophenotypic and cytogenetic profile as prior specimens, consistent with persistent AML and indicating failure to re-induction chemotherapy. The patient declined further chemotherapy and eventually succumbed to disease within 6 months of diagnosis.
Discussion
It is well established that cytogenetic and molecular profile play a very important role in the prognostification of AML. We describe an interesting and important case of an AML with a rare t(7;14)(q21;q32) and trisomy 4 with poor clinical outcome. The t(7;14)(q21;q32) has been previously described in one case of AML with myelodysplasia-related changes and chronic lymphocytic leukemia (CLL) in 2 single case reports, without specific mention of clinical outcome in these patients. 3, 4 Even though the breakpoint bands involved in the translocation of those cases are similar, the IgH locus in our case moved from chromosome 14q32 to chromosome 7q21 but was not rearranged, as evidenced by absence of a break-apart signal. The significance and molecular effect of this difference is uncertain. In addition to t(7;14), our patient was noted to have trisomy 4, which is a rare cytogenetic abnormality in AML. Small case series examining AML with isolated trisomy 4 show, in one study, that patients achieve complete remission up to 76.6% and, in another study, that they may have an average overall survival of 28 months. 5, 6 Reported literature suggests the prognosis of AML patients with this isolated trisomy may have a poorer prognosis compared to those with intermediate risk cytogenetics. 6 Given that trisomy 4 is associated with intermediate to poor outcome when it is the sole abnormality in AML, it is likely that this aberration has a contributory additive role in this patient's rapid clinical decline outcome, possibly via collaborative pathways in leukemogenesis. However, since our patient did have a precipitously rapid decline in her clinical status compared to other published reports of trisomy 4 alone, we can only speculate that t(7;14) had an important contributory role in this patient's poor clinical outcome. Finally, molecular aberrations in NPM1 were shown to have a statistically significant worse prognosis in AML cases with isolated trisomy 4. 5 Since we are unable to perform retrospective molecular studies owing to technical issues, we are unable to ascertain if the patient has any additional molecular aberrancies.
The role of t(7;14) in AML is in itself worth mentioning as the 14q32 region containing the IgH locus is infrequently involved in myeloid neoplasms. With regard to the 7q21 locus, 2 plausible genes located near and around 7q21 that may be involved in the t(7;14) and resultant leukemogenesis are CDK6 and ERWE-1, both of which are involved in cell cycle regulation, cell proliferation, and/or apoptosis. 3, 7 Cell division is regulated by checkpoints to ensure appropriate progression from 1 phase of the cell cycle to another. Cyclin-dependent kinases are essential in the progression of the cell from G1 phase into the DNA synthesis phase (S phase). Activation of CDK6 by D cyclins allows for phosphorylation of retinoblastoma (Rb) protein and release of transcription factor (E2F), allowing the cell to begin DNA replication. Another important gene, ERVWE-1, that has been implicated in cell proliferation and anti-apoptosis functions lies 127kb upstream to CDK6 on 7q21.2 region and may also be important in the pathogenesis and poor prognosis of AML with the t(7;14)(q21;q32). ERVWE-1 is part of the human endogenous retroviruses that have been integrated and preserved in the human genome. 8, 9 This gene has sequences that code for a matrix, capsids, nucleocapsids, and envelope glycoproteins. Of these, the envelope glycoprotein sequence of this gene region is preserved, whereas the other sequences are disrupted by stop codons. The encoded envelope glycoprotein syncytin-1 has been noted to have multiple functions and has been implicated in cell proliferation and anti-apoptosis. However, the specific functions of this protein in cell proliferation and anti-apoptosis are not well studied in vivo. In vitro using cell cultures simulating placental trophoblasts show that syncytin-1 promotes transition of the cell from G1 phase to S phase like CDK6. 10 In addition, this protein may induce upregulation of BCL-2 and decreased caspase 3 activation, preventing apoptosis and allowing for continued cell proliferation.
11
Given the role of syncytin-1 (encoded by ERVWE-1 gene in the 7q21 locus) in uncontrolled cell proliferation and decreased cell apoptosis, it is indeed an attractive candidate gene in AML with t(7;14)(q21;q32), other than CDK6.
In summary, we describe a rare t(7;14)(q21;q32) and concomitant trisomy 4 in acute myeloid leukemia that appears to portend very poor response to standard chemotherapy regimens and thus a poor clinical outcome. The exact mechanism via which this rare translocation and trisomy 4 results in leukemogenesis is yet to deciphered, but we hypothesize a putative additive role of these two aberrations. Two strong candidates in the 7q21 locus include
